Abstract. The ultimate goal of the biomedical informatics project PrognoChip is the identification of classification and prognosis molecular markers for breast cancer. This requires not only an understanding of the genetic basis of the disease, based on the patient's tumor gene expression profiles but also the correlation of this data with knowledge normally processed in the clinical setting. In this paper, we present the Mediator component of the PrognoChip Integrated Clinico-Genomics Environment (ICGE), through which the integration of the clinical and genomic information subsystems is achieved. The biomedical investigator can form clinico-genomic queries through the webbased graphical user interface of the Mediator. This is split into several query forms, allowing cancerous sample selection (along with their associated gene expression profiles and patient characteristics), based on criteria of interest. After a query is formed, the Mediator translates it into an equivalent set of local subqueries, which are executed directly against the constituent databases. Then, results are combined for presentation to the user and/or transmission to the Data Mining tools for analysis.
Introduction
PrognoChip is an ongoing project that aims at the identification of molecular markers for the classification and prognosis of breast cancer, based on the correlation of patients' clinico-histopathological parameters and therapy response with their tumor gene expression profiles [12] . To achieve this, PrognoChip joins forces from different scientific disciplines: Molecular Biology (FORTH-IMBB), Medicine (Univ. General Hospital of Heraklion -PAGNH, and PROLIPSIS, a breast cancer center), and Computer Science (FORTH-ICS). The main medical and molecular biology tasks within PrognoChip are:
Medicine/ Tissue collection & Histopathology: surgical specimens are collected from breast cancer patients that undergo any surgical type of treatment. As soon as the specimen is removed from the patient, it is carried immediately to the histopathology department, where sections are taken from the growing edge of the tumor for (a) histopathological and immunohistochemistry analysis, and (b) identification of their gene expression profiles through DNA Microarray technology. [1, 10] : A DNA microarray of long oligonucleotide probes has been designed, representing all known human genes, approximately 35,000 different reporters (oligonucleotides) of 27,000 different genes. Oligonucleotide probes are spotted on four activated glass slides (arrays). A common "reference" material has been decided for the study, consisting from a defined set of cell-line extracts, ensuring accurate quantitation of gene expression for most of the genes. Additionally, RNA extraction, amplification, and fluorescent labeling protocols have been developed, allowing the analysis of small samples. After array hybridization, fluorescence intensity images are acquired. From these images, fluorescence intensities (raw hybridization data) are obtained, using dedicated image analysis software. Raw hybridization data are analyzed to generate Gene Expression data, expressing through a Ratio Value (per spotted reporter/gene), if the gene in the cancerous tissue is over-expressed, under-expressed, or equally expressed with respect to the "reference" tissue. To intelligently correlate clinical and genomic information towards PrognoChip's goal of individualized medicine, an Integrated Clinico-Genomics Environment (ICGE) has been implemented (see Figure 1) , consisting of (a) a Clinical Information System to keep patients' clinical information (i.e., clinical, laboratory, and histopathological information), (b) a Genomic Information System to manage the specifications of the respective DNA microarray experiments (i.e., microarray design, hybridizations, etc.), analyze the raw hybridization data, and store the samples' gene expression profiles, (c) a middleware layer, called the PrognoChip Mediator, for the integration of the Clinical and Genomic Information Systems, and (d) a Data Mining layer, realized by an integrated set of tools, for the intelligent processing of the retrieved clinico-genomic data, knowledge extraction, and visualization.
Molecular Biology/ Microarrays

Mediator
In this paper, we present the PrognoChip Mediator, and we give a brief overview of the Clinical and Genomic Information Systems. The PrognoChip Mediator offers a powerful web-based graphical user interface for forming clinico-genomic queries. This is split into several query forms, allowing cancerous sample selection (along with their associated gene expression profiles and patient characteristics), based on criteria of interest. After a query is formed, the Mediator translates it into an equivalent set of local subqueries, which are executed directly against the constituent databases. Then, results are combined and an output XML file is formed for presentation to the user and/or transmission to the Data Mining tools for analysis.
The rest of the paper is organized as follows. In Section 2, the subsystems integrated by the PrognoChip Mediator are briefly presented. In Section 3, we describe the architecture and interface of the PrognoChip Mediator. Finally, Section 4 concludes the paper, including example Data Mining scenarios.
The Integrated Subsystems
The PrognoChip Mediator integrates the Clinical Information System, the Genomic Information System, and the Gene Ontology (GO) Database [2] .
GO is a well-known ontology for the annotation of genes/gene products in terms of the biological processes in which they participate, the particular molecular functions that they perform, and the cellular components in which they act. In particular, GO consists of 3 independent taxonomies, namely GO Biological Process, GO Molecular Function, and GO Cellular Component. Ontology terms are associated with a GO id and a human readable GO name. Each gene product annotation should be accompanied by an evidence code, indicating the type of evidence that supports it. The three GO taxonomies are stored in the GO Database, which is publicly available.
The Clinical Information System
The Clinical Information System (Clinical IS) of PrognoChip manages the Electronic Health Record (EHR) of breast cancer patients, by storing information related to patient identification and demographic information, medical history (past diseases, surgeries, medications, gynecological history), patient risk factors, family history of malignancy, clinical examinations and findings, results of laboratory exams (mammography, ultrasound, hematological and biochemical exams, etc.), histopathologic evaluation and TNM staging (indicating Tumor size, Lymph node involvement, and Metastatic spread), pre-surgical and post-surgical therapies, as well as therapy effectiveness and follow-up exams. The Clinical IS is actually the extension with breast cancer concepts of a patient-oriented Integrated Health Care Environment [16] , called Integrated Care Solutions, developed by the Biomedical Informatics Lab of FORTH-ICS. The system is based on a client-server architecture, runs on a PC Server, and uses an SQL Server database backend. For the needs of PrognoChip, the Clinical IS has been installed at PAGNH and PROLIPSIS.
The Genomic Information System
The Genomic Information System (Genomic IS) of PrognoChip is based on the BioArray Software Environment (BASE) [14] . BASE is a MIAME-compliant [3] database and analysis platform designed to be installed in any microarray laboratory and serve many users simultaneously via the web. BASE was developed by Lund University and is a free software release under the GNU General Public License. It runs on a Linux Server using a MySQL database backend.
In short, BASE manages biomaterials (samples, extracts, labeled extracts), reporters/genes and related annotations, as well as array production and hybridizations. When all related information is available, raw hybridization data can be stored. Several scanners and image processors are supported. Each step of a microarray experiment is associated with a protocol description. Raw hybridization data (called, measured bioassay data in MAGE-OM: MicroArray and Gene Expression -Object Model [6]) can be organized in Experiments and normalized. Normalization plug-ins are already installed in BASE, but it is also possible to develop and install your own plug-ins. Normalization is performed in a hierarchical way and several normalization methods (such as, lowess, median) can be performed to refine intermediate results.
In PrognoChip, BASE was extended and enhanced in order to ease a biologist's task, and to provide more functionalities (eg., improved result annotation, sorting of results based on user-selected fields, etc.). Moreover, several quality indicators have been added to Extracts, Labeled Extracts, and Hybridizations to provide users with the capability of storing and reviewing the quality of their experiments. Furthermore, new raw hybridization data fields have been added and reporter/gene annotations have been extended with the type of the reporter and ids to public databases, such as Ensembl [4] and EMBL [5] , as well as, Gene Ontology (GO) ids/names/evidence codes. Experiments participating in PrognoChip studies, called PrognoChip Experiments, are marked with a special flag. For these experiments, an integrity constraint verifies that the same (cancerous and "reference") samples are used in all participating hybridizations and that the designs of the participating arrays are different. This guarantees correspondence of a wet lab experiment to a single dry lab experiment, where four different arrays are used to cover the whole human genome. For the needs of PrognoChip, a Print-tip Loess -no Background Correction normalization plug-in [7] (developed by Uppsala University) has been installed and several PrognoChip normalization procedures have been defined, which are formed by a fixed sequence of normalization plug-in calls with their associated parameters. The Genomic IS has been installed in the participating molecular biology lab at FORTH-IMBB.
The PrognoChip Mediator
The (horizontal 1 ) integration of the Clinical ISs, the Genomic IS, and the GO database is achieved through the PrognoChip Mediator (see Figure 1 ), which offers a virtual common query model while data is stored only in the constituent heterogeneous databases. The Mediator is developed using the ASP programming language and ODBC for accessing the corresponding databases.
The (authorized) biomedical investigator can form clinico-genomic queries through the web-based graphical user interface of the Mediator. This is split into several query forms, whose links are found in the left frame of the web interface (see Figure 2) . Through these forms, the user can specify criteria for selecting tumors: (i) excised from patients with a clinical profile of interest, (ii) having histopathologic characteristics of interest, and (iii) participating in a PrognoChip microarray experiment of specified quality and characteristics. Returned tumors are accompanied with desirable clinico-genomic information and, in particular, their gene expression profiles. In all forms, numerical and datetime fields are queried as ranges. Additionally, some fields are dependent on a parent field and are appearing only if the parent field takes a specific value.
After the selection criteria of a clinical or genomic form are saved, a complex SQL subquery, or part of it, is formed which is temporarily stored in the Mediator DB. The final SQL subqueries are formed only after the desired output fields are selected by the user. Then, the final subqueries are submitted to the corresponding Clinical ISs or Genomic IS for evaluation. Below, we review the PrognoChip Mediator query forms:
Search by Sample Form
In the Search by Sample form, the user specifies the sample names on which the clinico-genomic selection criteria will be applied, as long as these belong to patients participating in the PrognoChip study. If no sample names are specified then all tumors of breast cancer patients participating in the PrognoChip study are considered.
Clinical Query Forms
In the Past Breast Diseases form, the user specifies patient's past breast diseases, such as fibroadenoma and fibrocystic changes, selecting these from a predetermined list of breast diseases. For each selected disease, the user can specify if it occurred on the left, right, or both breasts, as well as the number of years that have passed before tumor surgery. Criteria on selected diseases can be combined with either an AND or an OR logical operator.
In the Gynecological History form, the user specifies the age of menarche, the patients's menopausal status, the age at menopause (if the patient is postmenopausal), the number of pregnancies, the number of child births, the age at first child birth, and the lactation duration (if the patient has breastfeeded).
In the Hormone Intake form, the user specifies the total duration of hormone intake for conception, regulation, prevention, and contraception, respectively.
In the Other Risk Factors form, the user specifies the patient's age, body mass index, and smoking habits, including number of smoked cigarettes per day, years of smoking, and years passed after quitting (if the patient has quitted smoking).
In the Family History of Malignancy form, the user specifies patient's relatives that have developed cancer sometime in their lives, along with the age that this happened. The various degrees of kinship, as well as types of cancer are selected from corresponding pull-down menus. The specified criteria on the different relatives can be combined by either an AND or an OR logical operator.
Fig. 2. The Histological Type query form
In the Breast -Nipple Findings form, the user specifies patient's current breast findings (eg., skin invasion) and current nipple findings (eg., retraction), selecting these from a predetermined list of breast and nipple findings. For each selected finding, the user can specify if it occurred on the left, right, or both breasts. Additionally, in this form the user specifies the clinical TNM stage of the patient before pre-surgical chemotherapies and radiotherapies, where the T, N, M fields are queried as ranges.
In the Blood Tumor Markers form, the user selects from a predetermined list of blood tumor markers, such as CA15-3 and CEA, the tumor markers of interest. Then, for each selected tumor marker, the user can specify a range of values.
In the Therapies Before Surgery form, the user specifies from a predetermined list, the chemotherapies undergone by the patient before surgery (for shrinking tumor size). For each selected chemotherapy, the user specifies if the therapy is intravenous or local, the number of cycles, and patient's response to the therapy. Similarly, the user specifies from a predetermined list, the radiotherapies undergone by the patient before surgery. In this form, the user also specifies the clinical TNM of the patient after completion of the course of pre-surgical chemotherapies and radiotherapies, respectively.
In the Therapies After Surgery form, the user specifies from predetermined lists, the chemotherapies, radiotherapies, hormonotherapies, and immunotherapies undergone by the patient after surgery. Additionally, the user can specify other taken actions.
In the Therapies Effectiveness form, the user specifies the Disease Free Survival (DFS) and the Overall Survival (OS) of the patient, as well as if she has presented metastasis or died due to relapse. Of course, if the patient has not presented metastasis (resp. is alive) then only a lower-bound query on DFS (resp. OS) is meaningful.
Histopathologic Query Forms
In the Histological Type form, the user specifies the histological type of the tumor, i.e., Ductal Carcinoma (in situ, microinvasive, invasive), Lobular Carcinoma (in situ, invasive), and Carcinoma of Specific Character, by clicking the corresponding checkbox, as shown in Figure 2 . When the checkbox is clicked, the fields associated with the particular histological type are appearing. Note that in the case of an invasive ductal carcinoma, the user can specify the number of invasions that satisfy certain criteria.
In the Carcinoma, Other form, the user specifies the diameter, grade, and histological TNM of the tumor. It also specifies, (i) if there is lymphatic, venous, perineural, skin, and/or nipple invasion (Paget or non-Paget type), (ii) invasion on the excision margins of the tumor, and (iii) if the tumor is a phylloides tumor or a lesion with atypia. In the latter case, the grade of atypia can also be specified.
In the Lymph Nodes form, the user specifies the number of lymph nodes, sentinel lymph nodes, local lymph nodes, and intrammamary lymph nodes, respectively, that have X, Y, and Z dimensions within a certain range, present metastatic invasion, capsule invasion, and/or invasion of the adipose tissue of axilla. In the case of metastatic invasion, the user can select the type of metastasis from a pull-down menu.
In the Immunohistochemical Tumor Markers form (see Figure 3) , the user selects immunohistochemical tumor markers, such as ER, PR, HER-2, etc., from a pull-down menu and for each one of them, he/she specifies the percentage of tumor cell staining, the intensity of staining, the tumor marker score, and internal and external positive control information. Additionally, the user can indicate if the HER-2 FISH score is positive or negative. For example, in Figure 3 , the user selects tumors that are both HER-2 and ER positive.
Genomic Query Forms
In the MicroArray Experiment form, the user specifies the channel of the cancerous tissue in the microarray experiment (Channel 1, if the tumor extract is labeled with the Cy3 fluorescence, or Channel 2, if the tumor extract is labeled with the Cy5 fluorescence). As it will become obvious later, this is needed for the correct interpretation of the normalized data. The user also specifies the dates and qualities of the experiment hybridizations, as well as the name of the desired PrognoChip normalization procedure (selected from a pull-down menu).
Fig. 3. The Immunohistochemistry Tumor Markers query form
In the Reporter Filtering form (see Figure 4) , the user can filter the reporters appearing in the gene expression profiles of the selected tumors, based on (i) their library name, (ii) their associated GO Biological Process, GO Molecular Function, and GO Cellular Location names, and (iii) their GO annotation evidence codes. GO names can be inserted manually into the corresponding textboxes but they can also be automatically inserted by accessing the local installation of the GO database and retrieving the direct children or descendants of a particular GO name, specified by the user. Criteria on GO Biological Process, GO Molecular Function, and GO Cellular Component annotations, respectively, can be combined by either an AND or an OR operator. Additionally, the user can specify a list of evidence codes of interest. For example, in Figure 4 , the user specifies that he/she is interested only in the reporters of the library "Human Operon v.3" and annotated by the GO Biological Process term "signal transduction" or any of its descendants. In this case, the user enters signal transduction in the GO Biological Process names textbox, and also enters the same GO name in the Add all descendants of textbox, clicking on the Add button. At this time, a query asking "for all descendants of signal transduction in the GO Biological Process taxonomy" is created and submitted to the local GO database. All GO names in the answer are inserted automatically into the GO Biological Process names textbox. Then, the user clicks on the OR radio button (to the right), indicating that annotation criteria should be combined by the OR operator. The user also specifies that he/she is interesting only in annotations, supported by IC (inferred by curator) or IDA (inferred by direct assay) type of evidence.
Select Page
After patient/tumor criteria specification, the user selects the clinical, histopathologic, and genomic fields of interest that will accompany the cancerous sample in the output. This is done in the Select Page (the top half of which is shown in Figure 5 ), which is appearing after pressing the Make Query button, shown in Figure 2 . Moreover, in the Select Page, the user specifies the gene expression measures of interest and the annotations that should accompany the reporters, selected based on the criteria of the Reporter Filtering form. For example, in Figure 5 , the user specifies that he/she is interested in the pre-surgical chemotherapies and radiotherapies of the selected patients. Additionally, in the Select Page, the user can specify that from the normalized data fields, he/she is interested in both the log 2 (intensity1/intensity2) and log 2 (intensity1 + intensity2) measures (corresponding to different gene expression measures), where intensity1 and intensity2 are the normalized fluorescence intensities of the tissues placed in Channel 1 and Channel 2 of the microarray experiment, respectively. Moreover, the user can specify that, from the reporter annotations, he/she is interested in the HUGO Gene Nomenclature Committee name of the corresponding gene, the Ensembl gene id, and the corresponding GO Biological Process annotations.
In the Select Page, the user also specifies the Clinical ISs to which the clinical subqueries will be submitted. For example, in Figure 5 , the user selects only the Clinical IS of PAGNH. Though in PrognoChip, there are only two participating Clinical ISs, our system can handle any number of these. Information on the participating Clinical ISs and Genomic IS is stored in the Mediator DB (see Figure 1) and handled by the administrator through the Administration form. 
Submission of Final Subqueries & Result Composition
The Mediator is now able to form the final subqueries that will be submitted to Clinical and Genomic ISs. Due to the fact that gene expression data are much larger in size than patient clinical data, the Mediator first submits the clinical subqueries to the Clinical ISs. Subquery results are then combined, providing not only the selected clinico-histopathologic attributes for the patients satisfying the user-specified, clinicohistopathologic criteria but also their corresponding tumor names. The latter are used in forming the final SQL subqueries that will be submitted to the Genomic IS. 
Conclusions
In this paper, we presented the PrognoChip Mediator, which is part of the Integrated Clinico-Genomics Environment (ICGE) of PrognoChip. The Mediator integrates clinical and genomic data from the respective information systems, through a powerful web-based graphical user interface for submitting clinico-genomic queries. Mediator replies are not only useful by themselves, but they can also support decision making operations, enabled by the Data Mining layer of ICGE, through knowledge extraction and data mining methodologies [7, 13] . Example scenarios include:
• Retrieve the tumor gene expression profiles of patients that meet clinical (specifically, clinico-histopathological) profile A and clinical profile B. Then, by the appropriate data-mining and gene-selection methods, find the genes that best discriminate between these two groups (i.e., disease-related gene markers).
• By clustering the tumor gene expression profiles, search and identify the respective clinical description of the corresponding patients. Then, with the application of feature selection and/or classification methods, identify potential interesting and indicative patient clinical profiles.
Arguably, ontology-based integration systems, such as TAMBIS [15] , ONTOFUSION [11] , and BACIIS [8] , are more flexible and scalable than the PrognoChip Mediator. This is because, considering a single domain conceptualization through an ontology, they accept ontology-based queries, which they dynamically break into local subqueries, based on pre-defined ontology-to-data source mappings. However, these systems are not powerful enough to (i) offer the user friendliness of our system, and (ii) support the complexity of the local SQL subqueries and additional main-memory processing, required to return the desired data and data associations between the Genomic and Clinical Information Systems of PrognoChip.
Future work concerns further optimization of the PrognoChip Mediator and performance evaluation based on real data.
